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Abstract 
Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects 
young adult women. Choroidal neovascularization (CNV) is one of the complications that can 
develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal 
osteoma treated with intravitreal ranibizumab. A 57-year-old lady presented with painless 
loss of vision with a right-eye visual acuity of 20/800. Fundus examination showed a well-
demarcated yellowish peripapillary choroidal osteoma with associated retinal and subretinal 
hemorrhage due to CNV. Three intravitreal ranibizumab injections at monthly intervals were 
given and her visual acuity improved to 20/30 following treatment. After 1.2 years of follow-
up, the right eye visual acuity was maintained at 20/30 with no evidence of CNV recurrence. 
Our findings suggest that intravitreal ranibizumab may be an effective therapeutic option for 
treating CNV secondary to choroidal osteoma. 
 
Introduction 
Choroidal osteoma is a rare ossifying benign tumor of the choroid [1]. It was first 
described by Gass et al. in 1978, when they reported the development of yellowish, 
slightly elevated juxtapapillary choroidal lesions with sharp geographic borders in four 
healthy young women [1]. The tumor is usually unilateral and develops in the second or 
third decade of life. Long-term longitudinal studies have shown that 50% of patients 
with choroidal osteoma had a final vision of 20/200 or worse [2, 3]. Tumor growth, 
tumor decalcification, and the development of choroidal neovascularization (CNV) can 
cause substantial visual loss [2]. Thermal laser photocoagulation [4], transpupillary  
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thermotherapy [5], photodynamic therapy (PDT) with verteporfin [6], and more 
recently intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy like 
bevacizumab [7–9] have been reported as treatment options of CNV secondary to 
choroidal osteoma with variable results. There has only been one previous publication 
of the use of intravitreal ranibizumab for the treatment of CNV due to choroidal 
osteoma [10]. However, the patient was only followed for 6 months and the long-term 
outcome was not available. We hereby report a patient with CNV secondary to 
choroidal osteoma treated with intravitreal ranibizumab with long-term follow-up. 
Case Report 
A 57-year-old lady presented with right-eye painless visual loss for 10 days. Her past ocular and 
medical histories were unremarkable. On presentation, the visual acuity was 20/800 in the right eye. 
Fundus examination of the right eye revealed a large well-demarcated yellowish peripapillary choroidal 
lesion of 10-disc area with associated retinal and subretinal hemorrhage involving the central macula 
(fig. 1a). Fluorescein angiography (FA) of the right eye showed subfoveal CNV with late leakage (fig. 1b 
and c). A diagnosis of right eye CNV secondary to choroidal osteoma was made. After discussing the 
treatment options with the patient, she underwent intravitreal injections of 0.5 mg ranibizumab 
(Lucentis, Novartis Inc., Basel, Switzerland). Three loading doses at monthly intervals were given. 
Following the three ranibizumab injections, the retinal and subretinal hemorrhage completely absorbed 
(fig. 2a) and the right eye visual acuity improved to 20/30. Repeat FA at 3 months demonstrated fibrosis 
of the CNV with absence of fluorescein leakage (fig. 2b and c). The patient was followed for 1.2 years 
after presentation and her BCVA remained stable at 20/30 with no recurrence of CNV. 
Discussion 
Choroidal osteoma is an unusual intraocular tumor of unknown etiology and one of 
the most important causes of visual loss in patients with choroidal osteoma is the 
development of CNV [2, 3]. Shields et al. [2] reported the long-term outcome of 61 
patients with choroidal osteoma and it was shown that patients with choroidal osteoma 
have a 31% chance of developing CNV by 10 years. A similar study by Aylward et al. [3] 
demonstrated that 47% of 36 patients with choroidal osteoma developed CNV. Thermal 
laser photocoagulation has been described as a treatment option for CNV secondary to 
choroidal osteoma but with limited success [4]. The poor outcome of thermal laser 
photocoagulation was speculated to be due to lack of pigmentation within the tumor, as 
well as due to the thin and degenerated retinal pigment epithelium overlying the tumor 
resulting in unsatisfactory laser reaction [4]. PDT with verteporfin and transpupillary 
thermotherapy have also been described as treatment options for CNV secondary to 
choroidal osteoma, but reports on favorable treatment outcomes were scarce [5, 6]. 
More recently, intravitreal injections of anti-VEGF agents such as bevacizumab and 
ranibizumab were described as possible interventions for CNV secondary to choroidal 
osteoma [7–10]. This was inspired by the safe and effective use of intravitreal anti-
VEGF antibodies in treating CNV in cases of neovascular age-related macular 
degeneration as well as other types of CNV. Song and Roh [10] first reported the use of 
intravitreal ranibizumab in a patient with CNV secondary to choroidal osteoma and 
observed regression of CNV as well as recovery of visual acuity. In our case, there was 
considerable visual improvement from 20/800 to 20/30 after three loading doses of 
intravitreal ranibizumab injections. Moreover, there was no evidence of CNV 
recurrence 15 months after initial treatment. Our case further supports the role of 
intravitreal ranibizumab in the treatment of CNV secondary to choroidal osteoma.  
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Fig. 1. a Pretreatment mosaic fundus photograph of the right eye showing well-demarcated yellowish 
white choroidal osteoma with retinal and subretinal hemorrhage at central macula. b Early- and 
c late-phase fluorescein angiography showing a subfoveal hyperfluorescent lesion due to choroidal 
vascularization associated with blocked fluorescence due to hemorrhage. 
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Fig. 2. a Mosaic fundus photograph of the right eye at 3 months following intravitreal ranibizumab 
treatment showing complete resolution of macular hemorrhage with mild fibrosis at the inferior 
border of the choroidal osteoma. b Early- and c late-phase fluorescein angiography showing fibrosis of 
the choroidal neovascularization with absence of leakage. 
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